|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Avanir_Pharmaceuticals
gptkb:Astex_Pharmaceuticals
|
|
gptkbp:advertising
|
gptkb:Yoshihiro_Kato
gptkb:Taro_Iwamoto
Masahiro Kato
|
|
gptkbp:awards
|
Forbes Global 2000
Top_100_Global_Innovators
Best_Workplaces_in_Japan
|
|
gptkbp:employees
|
approximately 47,000
|
|
gptkbp:founded
|
1964
|
|
gptkbp:founder
|
gptkb:Akihiko_Otsuka
|
|
gptkbp:global_presence
|
Operations in over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Otsuka Pharmaceutical Company
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:notableEvent
|
gptkb:Samsca
gptkb:Rexulti
Abilify
Seroquel
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Takeda_Pharmaceutical_Company
gptkb:Bristol-Myers_Squibb
gptkb:Helsinn_Healthcare
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:philanthropy
|
gptkb:Otsuka_Medical_Research_Institute
gptkb:Otsuka_Foundation
Otsuka_Pharmaceutical_Co.,_Ltd._Scholarship_Program
|
|
gptkbp:products
|
Consumer healthcare products
Prescription drugs
Nutritional products
|
|
gptkbp:research_focus
|
Oncology
Cardiovascular diseases
Infectious diseases
Central nervous system disorders
|
|
gptkbp:revenue
|
$11.5 billion (2020)
|
|
gptkbp:subsidiary
|
gptkb:Otsuka_Pharmaceutical_Co.,_Ltd.
gptkb:Otsuka_America_Pharmaceutical,_Inc.
|
|
gptkbp:sustainability
|
Environmental initiatives
Ethical business practices
Social responsibility programs
|
|
gptkbp:website
|
www.otsuka.com
|